Sarepta Therapeutics Inc. (SRPT)
Sarepta: Should Investors Run For The Exit?
Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolated incident, influenced by the patient's recent CMV infection, and not indicative of systemic issues. With over 800 patients treated and no similar cases, we expect the stock to recover, presenting a buying opportunity for risk-tolerant investors.
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD).
3 Gene Therapy Stocks to Watch Amid Industry Turmoil
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.
Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has died following treatment with its gene therapy ELEVIDYS. Although acute liver injury is a known potential side effect of ELEVIDYS and similar therapies, this level of severity had not been previously reported, the company said in a statement.
Sarepta Therapeutics' stock falls after patient dies of liver failure
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
Sarepta says patient dies after treatment with gene therapy
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Sarepta Therapeutics' stock is at 52-week lows despite strong Q4 earnings and promising clinical updates, reflecting broader biotech sector challenges and investor sentiment. Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD, and DM1, with significant market potential, though not as large as DMD.
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Gena Wang - Barclays Andrew Tsai - Jefferies Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Joe Schwartz - Leerink Partners Gil Blum - Needham & Company Ritu Baral - TD Cowen Brian Skorney - Baird David Hoang - Deutsche Bank Ry Forseth - Guggenheim Securities Priyanka Grover - JPMorgan Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore Sami Corwin - William Blair Leo Watson - Mizuho Operator Good afternoon. And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago.
